Ulcerative Colitis

New research suggests bacteria used for beer and bread digestion could potentially be beneficial for combating yeast infections and autoimmune diseases like Crohn's disease.

From inflammatory bowel disease to Crohn's disease and everywhere in the gastrointestinal system in between 2014 was a big year for medical breakthroughs and potential future treatments. Here is a look at the top 10 stories.

A team of researchers recently reported that human genes may partially influence intestinal bacteria spurring inflammatory bowel disease (IBD) conditions like Crohn's disease (CD) and ulcerative colitis (UC).

Patients with irritable bowel syndrome with diarrhea (IBS-D) suffer not only the pain and discomfort of frequent loose stools, but fear of incontinence. For many patients, that results in panic and anxiety.

Modifying diet is one way to try to help patients with Irritable Bowel Syndrome (IBS). In a study reported in Gastroenterology, an Australian research team looked at the effects of lowering fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) vs. consuming a typical Australian diet.

Study results published in the European Respiratory Journal show that rates of inflammatory bowel disease (IBD) incidence have significantly increased in individuals with asthma or chronic obstructive pulmonary disease (COPD).

Serum-derived bovine immunoglobulin/protein isolate appears to be a safe and effective nutritional moiety in patients with refractory IBS-D or IBS-M.

A literature review published in Trends in Molecular Medicine suggests inflammatory bowel disease can be controlled by levels of inhibitors of apoptosis.

Monika Fischer, MD, talks about focusing research on patients with more severe IBD symptoms at 2014 ACG Annual Scientific Meeting in Philadelphia, PA.

Monika Fischer, MD, discusses the outcomes of a study assessing fecal microbiota transplantation for c. difficile infection at the 2014 ACG Annual Scientific Meeting in Philadelphia, PA.

Carol Burke, MD, FACG, FASGE, talks about her phase-3 placebo-controlled trial of Celecoxib in pediatric subjects with familial adenomatous polyposis (FAP) at the 2014 ACG Annual Meeting in Philadelphia, PA.

Carol Burke, MD, FACG, FASGE, discusses pediatric familial adenomatous polyposis (FAP) and colorectal cancer at the 2014 ACG Annual Scientific Meeting in Philadelphia, PA.

Study results show that eluxadoline may be useful in patients with diarrhea-predominant irritable bowel syndrome (IBS-D) who do not achieve symptom relief with loperamide.

Charles Bernstein, MD, FACG, discusses his research on Inflammatory Bowel Disease (IBD) treatment at the 2014 ACG Annual Meeting in Philadelphia, PA.

Study results show significant regional variations in the types of procedures and tests administered and the number of prescriptions written for patients with irritable bowel syndrome (IBS), as well as in the number of emergency department visits and hospital admissions.

Interim study results presented at ACG 2014 indicate that treatment with vedolizumab safely and effectively maintains long-term clinical remission and response in patients with Crohn's disease and ulcerative colitis.

Study results show that patients suffering from active inflammatory bowel disease (IBD) are at risk for poor prognoses following an initial myocardial infarction.

Inflammatory bowel diseases have an impact on the prognosis of multiple sclerosis, according to a study published in PLOS One.

Uceris (budesonide) is now approved in a new dose for the induction of remission in patients afflicted with active mild-to-moderate distal ulcerative colitis.

Scientists in Germany have discovered a causal relationship between psychological factors and symptoms of irritable bowel syndrome (IBS) after viewing high rates of anxiety and depression among IBS patients.

Patients of Indian ancestry living in the United States are at greater risk for all types of inflammatory bowel disease (IBD) than other American populations, according to a new study by Reenu Malhotra, MD, and colleagues published online in Clinical Gastroenterology and Hepatology on July 29, 2014.

Humira (adalimumab) is now indicated to treat children age 6 years and older with moderately to severely active Crohn's disease who have had an inadequate response to treatment with corticosteroids or immunomodulators.

After conducting a population-based, nationwide cohort study, researchers reported a relationship between inflammatory bowel disease (IBD), especially Crohn's disease (CD), and cervical neoplasia.

Advances in knowledge surrounding gastrointestinal conditions have paved the way for improvements in Crohn's disease (CD) treatment. To aid clinicians in managing patients with CD, the American Gastroenterological Association (AGA) created a clinical decision tool to effectively guide gastroenterologists throughout their decision-making process.

Experts have discovered a possible correlation between treatment with isotretinoin and decreased risk of inflammatory bowel disease, according to a study published in the Journal of American Medical Association Dermatology.

Researchers at Beth Israel Deaconess Medical Center (BIDMC) reported that proactive monitoring of dose adjustments of infliximab (IFX), one of the 4 anti-TNF-alpha proteins used to treat inflammatory diseases like Crohn's disease (CD), ulcerative colitis (UC), and inflammatory bowel disease (IBD), could prolong the effectiveness of treatment.

A research team with members at the University of California, Los Angeles (UCLA) has discovered genetic factors involved in a severe form of inflammatory bowel disease (IBS), pediatric ulcerative colitis.

Patients with irritable bowel syndrome experience less effective pain treatments, according to research from the University of Adelaide in Australia.

Researchers at the University of Leicester have developed a highly sensitive "electronic-nose" to identify the infectious bacteria Clostridium difficile that causes diarrhea, stomach cramps, and fever in patients.

Monitoring patients' own intestinal immune responses, researchers at Yale University have identified some of the bacterial culprits driving inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis.